Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pafuramidine - Immtech Pharmaceuticals

Drug Profile

Pafuramidine - Immtech Pharmaceuticals

Alternative Names: DB-289; Parfuramidine maleate

Latest Information Update: 28 Aug 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgia State University; University of North Carolina at Chapel Hill
  • Developer CombinatoRx; Immtech Pharmaceuticals
  • Class Antiparasitics; Benzamidines; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumocystis pneumonia; Malaria; African trypanosomiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued African trypanosomiasis; Cancer; Malaria; Pneumocystis pneumonia

Most Recent Events

  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 22 Feb 2008 Immtech Pharmaceuticals has discontinued all development programmes for pafuramidine in response to additional adverse events identified in a cohort of subjects in a safety study of the drug
  • 26 Dec 2007 Suspended - Phase-II for Malaria prevention in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top